FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:219-221 July 19, 2001 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Bernard and coworkers (March 8 issue)¹ conclude that recombinant human activated protein C (drotrecogin alfa [activated]) is efficacious in patients with sepsis. The placebo and treatment groups appeared to be closely matched, with one important exception: the interval between the diagnosis of sepsis and the administration of appropriate antibiotic therapy. The authors state only that appropriate antibiotic therapy was started within 48 hours of the diagnosis of severe sepsis.

It is axiomatic that the more severe the sepsis, the more important the requirement for prompt administration of appropriate antibiotic therapy. In a study of gram-negative bacterial sepsis . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Pastores, S M (2003). Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Postgrad. Med. J. 79: 5-10 [Abstract] [Full Text]